Prostate-specific antigen in patients with relapsed prostate cancer following endocrine treatment.
We assessed the relationship between changes in PSA and prognosis, as a possible reflection of tumour growth in patients who relapse following primary endocrine therapy. In 8 patients in whom no therapeutic change was attempted after PSA relapse, the PSA level increased exponentially. Their PSA-DT had a close positive relationship to the duration of survival after relapse (r = 0.79, p = 0.02). In 6 patients who received chemotherapy after relapse, PSA-DT between PSA relapse and initiation of chemotherapy also had a relationship to the duration of survival after relapse (r = 0.87, p = 0.05). It appears to be reasonable to conclude from these findings that the PSA-DT value is regarded to be a factor associated with prognosis in cases with an exponential increase in PSA after replase.
Kubota
Y
Y
Department of Urology, Yamagata University School of Medicine, Japan.
Yanai
H
H
Sasagawa
I
I
Suzuki
H
H
Nakada
T
T
Sugano
O
O
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000097:blood*; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy
D000970:Antineoplastic Agents; D017430:Prostate-Specific Antigen